Release of Research Publication using Tribody™ Technology onto Cancer Immunotherapy from Chiome Bioscience (JP) in collaboration with CEINGE (IT)

Tribodies combining blockers for PD-1, PD-L1 and LAG-3 showed enhanced activity on activating lymphocytes as compared to a mix of the parental mAbs, with lower toxicity on normal tissue.


The publication is released on a basis of the research using Chiome‘s Tribody™ technology. Tribody™ technology is one of our platform antibody engineering technologies that can generate multi-specific antibody applying for cancer immunotherapy. The research outcomes are published at International Journal of Molecular Sciences.

This research is conducted in collaboration with Ceinge Biotecnologie Avanzate (“Ceinge”), a nonprofit consortium research organization in Italy. We constructed novel bi-specific tribodies targeting different molecules involved in immune checkpoints. The tribody exhibited the retained binding activity to each target, increased immuno-modulatory effect to induce lymphocyte activation, and enhanced in vitro cytotoxicity against tumor cells. Tribody™ format could also reduce the production costs. Also, the molecular size is well suited for both tumor penetration and an acceptable half-life. Tribody could offer useful therapeutic applications, particularly in monotherapy-resistant cancer patients.

Ceinge is a non-profit consortium research organization in Naples , with entirely public capital, founded in 1983.
Ceinge operates in the field of molecular biology and advanced biotechnology applied to Human
Health. It is an excellence in Italy and abroad for the Research and Diagnostics of genetic diseases .

The Tribody™ technology enables the generation of multi-specific antibody products. This unique technology overcomes the key shortcomings of conventional mono- as well as of currently developed bi-specific antibody formats. Tribody™ enables creation of unique antibody by building multi-binding sites that bind to different antigen or epitope, which differentiate from conventional antibody. It is expected to generate antibodies against targets that could not be made into pharmaceuticals, and to generate antibodies that can be released from the combination drugs therapy.

Passariello, M., Yoshioka, A., Takahashi, K., Hashimoto, S., Rapuano Lembo, R., Manna, L., Nakamura, K., De Lorenzo, C., 2022. Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy. International Journal of Molecular Sciences 23, 3466.